Thyroid Stimulating Hormone Level at Diagnosis as a Predictor of Persistent Subclinical Hypothyroidism in Children with Down Syndrome

2018 ◽  
Vol 55 (7) ◽  
pp. 576-578
Author(s):  
Hariharan Vaikom Sankar ◽  
Krishnakumar Anjukrishna ◽  
Ismail Riaz
Keyword(s):  
Down Syndrome ◽  
Subclinical Hypothyroidism ◽  
Hormone Level ◽  
Thyroid Stimulating Hormone ◽  
Children With Down Syndrome ◽  
Stimulating Hormone

scholarly journals Approach to Subclinical Thyroid Diseas

1970 ◽  
Vol 26 (2) ◽  
pp. 91-96
Author(s):  
Satya Ranjan Sutradhar
Keyword(s):  
Subclinical Hypothyroidism ◽  
Thyroid Dysfunction ◽  
Hormone Level ◽  
Elevated Serum ◽  
Thyroid Stimulating Hormone ◽  
Good Evidence ◽  
Reference Ranges ◽  
Mineral Density ◽  
Asymptomatic Patients ◽  
Stimulating Hormone

Subclinical thyroid dysfunction is defined as an abnormal serum thyroid-stimulating hormone level and free thyroxine and triiodothyronine levels within their reference ranges. The prevalence of subclinical hyperthyroidism is about 2 percent. Subclinical hypothyroidism is found in approximately 4 to 8.5 percent of the population. Most national organizations recommend against routine screening of asymptomatic patients, but screening is recommended for high risk populations. The management of subclinical thyroid dysfunction is controversial. There is good evidence that subclinical hypothyroidism is associated with progression to overt disease. Patients with a serum thyroid-stimulating hormone level greater than 10 mIU/L have a higher incidence of elevated serum low density lipoprotein cholesterol concentrations; however, evidence is lacking for other associations. There is insufficient evidence that treatment of subclinical hypothyroidism is beneficial. A serum thyroid stimulating hormone level of less than 0.1 mIU/L is associated with progression to overt hyperthyroidism, atrial fibrillation, reduced bone mineral density, and cardiac dysfunction. There is little evidence that early treatment alters the clinical course. DOI: 10.3329/jbcps.v26i2.4187 J Bangladesh Coll Phys Surg 2008; 26: 91-96

Relation of Cardiac Dysfunction to Thyroid Stimulating Hormone in Children with Down Syndrome

2017 ◽  
Vol 34 (3-4) ◽  
pp. 145-156
Author(s):  
Mohamed E. Mowafy ◽  
Omneya I. Youssef ◽  
Heba S. Abd Elkhalek
Keyword(s):  
Down Syndrome ◽  
Cardiac Dysfunction ◽  
Thyroid Stimulating Hormone ◽  
Children With Down Syndrome ◽  
Stimulating Hormone

scholarly journals The role of subclinical hypothyroidism in lipid metabolism disorders

2019 ◽  
Vol 21 (2) ◽  
pp. 155-159
Author(s):  
A R Volkova ◽  
O D Dygun ◽  
O V Galkina ◽  
L A Belyakova ◽  
E O Bogdanova
Keyword(s):  
Lipid Metabolism ◽  
Subclinical Hypothyroidism ◽  
Hormone Level ◽  
Thyroid Stimulating Hormone ◽  
Control Group ◽  
Thyroid Peroxidase ◽  
Low Density ◽  
Igg Antibodies ◽  
Oxidized Lipoproteins ◽  
Stimulating Hormone

Subclinical hypothyroidism is common in general practice. The clinical significance of latent thyroid dysfunction has not yet been determined. The parameters of lipid metabolism and oxidative stress were studied in patients suffering from subclinical hypothyroidism between the ages of 18 and 50 years. They had a level of thyroid stimulating hormone ≥4 mIU/l, the level of free thyroxine was normal. The control group consisted of healthy individuals with thyroid-stimulating hormone level of 0,4-2,4 mIU/l. Thyroid status, thyroid peroxidase antibodies, lipid profile, malondialdehyde-modified low-density oxidized lipoproteins, antibodies to low-density oxidized lipoproteins, homocysteine were determined for all individuals. With the repeated determination of thyroid-stimulating hormone in 16,8% patients spontaneous recovery of thyroid-stimulating blood hormone level was observed, which was associated with lower values of thyroid-stimulating hormone and the absence of thyroid peroxidase antibodies. In the group of patients with thyroid stimulating hormone levels ≥7 mIU/l, the total cholesterol level was significantly (p=0,02) higher than in the control group. In patients with elevated values of malondialdehyde-modified oxidized low-density lipoprotein, thyroid stimulating hormone level of ≥7 mIU/l was more frequently detected. A negative correlation was found between the level of IgG antibodies to low-density oxidized lipoproteins and the concentration of free thyroxin. In the control group, the correlation was found between the concentration of IgG antibodies to low-density oxidized lipoproteins and the level of thyroid-stimulating hormone. In the group of subclinical hypothyroidism, the concentration of homocysteine was significantly (p=0,01) higher in men. In patients with subclinical hypothyroidism, more often hyperhomocysteinemia was detected compared with the control group. The results suggest that subclinical hypothyroidism is associated with initial changes in the metabolism of lipids and homocysteine.

Serum thyroid stimulating hormone level for predicting utility of thyroid uptake and scan

2020 ◽  
pp. 1-4
Author(s):  
Lauren Buehler ◽  
Alireza Movahed ◽  
Keren Zhou ◽  
M. Cecilia Lansang
Keyword(s):  
Hormone Level ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Uptake ◽  
Stimulating Hormone

scholarly journals A STUDY ON RELATION OF THYROID STIMULATING HORMONE LEVEL WITH SKELETAL METASTASIS IN CARCINOMA PROSTATE PATIENTS

2017 ◽  
Vol 6 (79) ◽  
pp. 5619-5625
Author(s):  
Minaxi Sharma ◽  
Krishna Gopal Sharma ◽  
Deepak Sethi ◽  
Rajveer Singh ◽  
Anjali Sethi
Keyword(s):  
Hormone Level ◽  
Skeletal Metastasis ◽  
Thyroid Stimulating Hormone ◽  
Carcinoma Prostate ◽  
Stimulating Hormone
Sign in / Sign up

Export Citation Format

Share Document